alpha(2) Adrenergic and imidazoline receptor agonists prevent cue-induced cocaine seeking.

摘要

BACKGROUND: Drug-associated cues can elicit stress-like responses in addicted individuals, indicating that cue- and stress-induced drug relapse may share some neural mechanisms. It is unknown whether alpha(2) adrenergic receptor agonists, which are known to attenuate stress-induced reinstatement of drug seeking in rats, also reduce cue-induced reinstatement. METHODS: Rats were tested for reinstatement of drug seeking following cocaine self-administration and extinction. We first evaluated the effects of clonidine, an agonist at alpha(2) and imidazoline-1 (I(1)) receptors, on relapse to cocaine seeking. To explore possible mechanisms of clonidine's effects, we then tested more specific alpha(2) or I(1) agonists, postsynaptic adrenergic receptor (alpha(1) and beta) antagonists, and corticotropin-releasing factor receptor-1 antagonists. RESULTS: We found that clonidine, and the more selective alpha(2) agonists UK-14,304 and guanfacine, decreased cue-induced reinstatement of cocaine seeking. The specific I(1) receptor agonist moxonidine reduced cue-induced as well as cocaine-induced reinstatement. Clonidine or moxonidine effects on cue-induced reinstatement were reversed by the selective alpha(2) receptor antagonist RS-79948, indicating a role for alpha(2) receptors. Prazosin and propranolol, antagonists at the alpha(1) and beta receptor, respectively, reduced cue-induced reinstatement only when administered in combination. Finally, the corticotropin-releasing factor receptor-1 antagonist CP-154,526 reduced cue-induced reinstatement, as previously observed for stress-induced reinstatement, indicating possible overlap between stress and cue mechanisms. CONCLUSIONS: These results indicate that alpha(2) and I(1) receptor agonists are novel therapeutic options for prevention of cue-induced cocaine relapse. Given that alpha(2) receptor stimulation is associated with sedation in humans, the I(1) agonist moxonidine seems to have substantial potential for treating addictive disorders.